Expert committee to assess pricing of Sanofi India's diabetes med Soliqua
A new product from French pharma major Sanofi’s (Euronext: SAN) Indian subsidiary, Soliqua (insulin glargine and lixisenatide recombinant fixed-dose combination), has recently been granted approval by the Central Drugs Standard Control Organization (CDSCO).
A multidisciplinary committee of experts, which advises India's National Pharmaceutical Pricing Authority (NPPA) on pricing-related matters, is now set to review the company's request for higher prices for Soliqua combinations.
A significant portion of Sanofi India's revenues are generated by the sale of oral anti-diabetes drugs and insulin. L0antus (insulin glargine injection), Toujeo (insulin glargine), and Amaryl (glimepiride) are some4 of Sanofi's leading brands in the anti-diabetic therapy market, accounting for more than 85% of its revenue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze